文献速递乳房整形与再造

生物合成补片用于假体乳房再造的结局:一项Meta分析

Outcomes in Implant-Based Breast Reconstruction Utilizing Biosynthetic Mesh: A Meta-Analysis.
PubMed 文献 · Aesthet Surg J · 2025-01-07

该Meta分析系统检索PubMed、MEDLINE和Embase,纳入24项研究、2167个假体再造乳房,评估TIGR、Vicryl、PDO、TiLOOP、Durasorb和Galaflex等生物合成补片的并发症。汇总血清肿5.26%、血肿2.5%、皮肤坏死5.5%、感染4.8%、假体丢失3.85%,作者认为并发症率低,生物合成补片可考虑用于乳房再造。

要点

  • 纳入24项研究、2167个假体再造乳房,涉及6种生物合成补片。
  • 汇总血清肿5.26%、血肿2.5%、皮肤坏死5.5%、感染4.8%、假体丢失3.85%。
  • 作者认为生物合成补片并发症率低,可考虑用于乳房再造。

核心结论

  • 尽管补片特性存在差异,报告的并发症率低。
  • 鉴于生物合成补片已证实的安全性、显著的成本优势以及相较脱细胞真皮基质可能减少短期并发症,乳房再造中应考虑生物合成补片选项。

研究设计与样本

  • 系统检索PubMed、MEDLINE和Embase,遵循PRISMA指南的Meta分析。
  • 纳入24项研究,涉及6种补片(TIGR、Vicryl、PDO、TiLOOP、Durasorb、Galaflex),共2167个假体再造乳房。
  • 采用比例结局合并,用Q和I2统计量评估异质性。

主要发现

  • 血清肿汇总发生率5.26%(Q=23.81%,I2=37.01%),来自13项研究。
  • 血肿汇总发生率2.5%(Q=0.25%,I2=58.27%),来自9项研究。
  • 皮肤坏死汇总发生率5.5%(Q=2.86%,I2=423.78%),来自10项研究。
  • 感染汇总发生率4.8%(Q=6.02%,I2=149.34%),来自21项研究。
  • 假体丢失汇总发生率3.85%(Q=6.55%,I2=129.07%),来自10项研究。

临床怎么用

  • 作者认为,鉴于生物合成补片已证实的安全性、显著的成本优势以及相较脱细胞真皮基质可能减少短期并发症,乳房再造中应考虑生物合成补片选项。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Biosynthetic mesh has become more popular for immediate breast cancer implant-based reconstruction as an alternative to acellular dermal matrix (ADM) for soft tissue support. This meta-analysis investigates the various biosynthetic options available as well as complications and outcomes. PubMed, MEDLINE, and Embase were systematically reviewed for studies investigating the following types of mesh, TIGR, Vicryl, PDO, TiLOOP, Durasorb, and Galaflex, and their associated outcomes. The meta-analysis was completed in accordance with PRISMA guidelines and was performed to determine overall complication rates in patients who underwent breast reconstruction with the use of mesh. Data were combined by a pooling of proportional outcomes as inherent to meta-analysis. Heterogeneity of included studies was assessed with the Q and I2 statistical analysis. A total of 24 studies investigating six different types of mesh in 2167 individual breasts undergoing implant reconstruction were included. Summary effect sizes were calculated for the complications. The pooled rate of seroma formation was 5.26% (Q = 23.81%, I2 = 37.01%) reported in 13 studies, hematoma formation was 2.5% (Q = 0.25%, I2 = 58.27%) reported in 9 studies, skin necrosis was 5.5% (Q =2.86%, I2 = 423.78%) reported in 10 studies, infection rate was 4.8% (Q = 6.02%, I2 = 149.34%) in 21 studies, and implant loss was 3.85% (Q = 6.55%, I2 =129.07%) reported in 10 studies. Overall, while differences in mesh characteristics exist, the reported rate of complications is low. Biosynthetic mesh options should be taken into consideration in breast reconstruction given their demonstrated safety, significant cost advantage, and potential decrease in short-term complications in comparison to acellular dermal matrices.

来源:Aesthet Surg J,查看原文。版权归原作者所有。

引用

  1. Arnautovic A, Williams S, Ash M, et al. Outcomes in Implant-Based Breast Reconstruction Utilizing Biosynthetic Mesh: A Meta-Analysis. Aesthet Surg J. 2025. PMID: 39763338. doi:10.1093/asj/sjaf002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。